First-in-human clinical trial for a vaccine to treat opioid use disorders enrolls first patients

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by researchers at the University of Minnesota Medical School. Funded by a grant from the National Institutes of Health, the trial will test the safety and potential efficacy of a vaccine that is designed to selectively prevent the euphoric and toxic effects of oxycodone.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news